Wedbush Raises Larimar Therapeutics Price Target to $12 Amid Steady Biotech Sector Momentum

Wedbush increased its price target for Larimar Therapeutics (LAR) to $12, up from $11, signaling incremental confidence in the company’s clinical progress. The biotechnology firm, focused on developing treatments for rare and severe autoimmune conditions, continues to advance its lead candidate through Phase 2 trials. While the upgrade is not accompanied by a change in rating, it reflects a reassessment of near-term valuation potential within the healthcare sector. The price target revision comes amid a broader uptick in investor interest toward small-cap biotech stocks, particularly those with proprietary platforms and defined patient populations. LAR’s performance remains closely tied to the success of its investigational therapy, which has shown promising early efficacy signals in preliminary data. The company is also exploring potential partnerships to accelerate commercialization, though no formal agreements have been announced. The healthcare sector benchmark index (XLV) has gained 3.7% year-to-date, driven by strong performance in specialty pharmaceuticals and gene therapy segments. Larimar Therapeutics’ stock, while still in the mid-$8 range, has outpaced the sector average over the past quarter. The IHX index, representing mid-cap healthcare firms, has also seen a 4.2% rise, underscoring growing appetite for innovation-driven companies with scalable platforms. Although the price target adjustment is incremental, it may prompt renewed attention from institutional investors tracking developmental-stage biotech firms. Analysts note that LAR’s ability to deliver pivotal trial results in the next 12 months will be critical to sustaining momentum. The upgrade does not reflect any new clinical data or regulatory developments but rather a recalibration of risk-adjusted returns given current market conditions.